FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Regeneron Pharmaceuticals Inc patents


      
Recent patent applications related to Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals Inc-related inventors


Search recent Press Releases: Regeneron Pharmaceuticals Inc-related press releases
Count Application # Date Regeneron Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
12015010573504/16/15 new patent  Syringe pistons, systems and methods
22015010696104/16/15 new patent  Humanized il-15 animals
32015009929604/09/15Promoter-regulated differentiation-dependent self-deleting cassette
42015010003004/09/15Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
52015008967803/26/15Non-human animals having a humanized signal-regulatory protein gene
62015008967903/26/15Non-human animals having a humanized signal-regulatory protein gene
72015008968003/26/15Human lambda light chain mice
82015007908703/19/15Vegf antagonist formulations
92015008246903/19/15Humanized il-7 rodents
102015006418903/05/15Method of treating cancer with dll4 antagonist and chemotherapeutic agent
112015006790103/05/15Production of fertile xy female animals from xy es cells
122015005622102/26/15Anti-prlr antibodies and uses thereof
132015005622202/26/15Anti-prlr antibodies and uses thereof
142015005900902/26/15Methods for making fully human bispecific antibodies using a common light chain
152015004706102/12/15Humanized m-csf mice
162015004706202/12/15Lincrna-deficient non-human animals
172015003733902/05/15Anti-activin a antibodies and uses thereof
182015004025302/05/15Genetically modified major histocompatibility complex mice
192015002441201/22/15Humanized fcgammar mice
202015001717601/15/15Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
212015001718201/15/15Methods for treating nasal polyposis by administering an il-4r antagonist
222015002022401/15/15Non-human animals with modified immunoglobulin heavy chain sequences
232015001056801/08/15Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
242015001302201/08/15Humanized il-6 and il-6 receptor
252015001302301/08/15Humanized il-6 and il-6 receptor
262014035637012/04/14Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
272014035637112/04/14Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
282014035637212/04/14Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
292014033134011/06/14Methods and compositions for generating a mouse
302014032221510/30/14Methods of inhibiting tumor growth by antagonizing il-6 receptor
312014031524910/23/14Inducible eukaryotic expression system
322014028987609/25/14Mice that make heavy chain antibodies
332014027164209/18/14Il-33 antagonists and uses thereof
342014027165309/18/14Human antibodies to respiratory syncytial virus f protein and methods of use thereof
352014027165809/18/14Anti-il-33 antibodies and uses thereof
362014027168109/18/14High affinity human antibodies to human il-4 receptor
372014027309509/18/14Serum-free cell culture medium
382014027548909/18/14Apelin fusion proteins and uses thereof
392014028315809/18/14Rodents with conditional acvr1 mutant alleles
402014025539009/11/14Method of treating rheumatoid arthritis with an anti-il-6r antibody
412014025541909/11/14Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
422014025542909/11/14Methods of treating autoimmune diseases with dll4 antagonists
432014025599509/11/14High affinity antibodies to human il-6 receptor
442014024866409/04/14Readily isolated bispecific antibodies with native immunoglobulin format
452014024350408/28/14Antibodies comprising chimeric constant domains
462014024546608/28/14Humanized t cell co-receptor mice
472014024546708/28/14Genetically modified major histocompatibility complex mice
482014024546808/28/14Non-human animals with modified immunoglobulin heavy chain sequences
492014022002308/07/14Method of treating osteoarthritis with an antibody to ngf
502014021377307/31/14Adam6 mice
512014019655007/17/14Systems and devices for sample handling
522014019976107/17/14Promoter-regulated differentiation-dependent self-deleting cassette
532014019340207/10/14Anti-pdgfr-beta antibodies and uses thereof
542014019459707/10/14Modified chimeric polypeptides with improved pharmacokinetic properties
552014018990007/03/14Mirna-regulated differentiation-dependent self-deleting cassette
562014017887906/26/14Compositions and methods for modifying cells
572014017990306/26/14High affinity human antibodies to human protease-activated receptor 2
582014015470106/05/14Humanized fc gamma r mice
592014015568906/05/14Methods of modifying genes in eukaryotic cells
602014015744506/05/14Low affinity fcgr deficient mice
612014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
622014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
632014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
642014013471905/15/14Recombinant cell surface capture proteins
652014013727505/15/14Hybrid light chain mice
662014013019305/08/14Mice that make vl binding proteins
672014013019405/08/14Mice that make vl binding proteins
682014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
692014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
702014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
712014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
722014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
732014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
742014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
752014007297903/13/14Isolating cells expressing secreted proteins
762014007298003/13/14Isolating cells expressing secreted proteins
772014007301003/13/14Methods of modifying eukaryotic cells
782014007558603/13/14Parental cell lines for making cassette-free f1 progeny
792014005690302/27/14Human antibodies to gfr alpha 3 and methods of use thereof
802014005690702/27/14Anti-asic1 antibodies and uses thereof
812014004473002/13/14Anti-pcsk9 antibodies with ph-dependent binding characteristics
822014004106802/06/14Methods of modifying eukaryotic cells
832014003333601/30/14Methods of modifying eukaryotic cells
842014003333701/30/14Methods of modifying eukaryotic cells
852014002363701/23/14Methods of modifying eukaryotic cells
862014001722801/16/14Humanized light chain mice
872014001722901/16/14Methods of modifying eukaryotic cells
882014001723801/16/14Methods of modifying eukaryotic cells
892014001769501/16/14Isolating cells expressing secreted proteins
902014001778101/16/14Methods of modifying eukaryotic cells
912014001778201/16/14Methods for modifying eukaryotic cells
922014001852201/16/14Methods of modifying eukaryotic cells
932014002012401/16/14Methods of modifying eukaryotic cells
942014002012501/16/14Methods of modifying eukaryotic cells
952014001345601/09/14Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
962014001345701/09/14Methods of modifying eukaryotic cells
972013034453812/26/13Human antibodies to the glucagon receptor
982013034010412/19/13Humanized il-7 rodents
992013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
1002013032326012/05/13Stabilized formulations containing anti-dll4 antibodies
1012013032326112/05/13Purified antibody composition
1022013032378812/05/13Production cell line enhancers
1032013032379012/05/13Human lambda light chain mice
1042013032379112/05/13Restricted immunoglobulin heavy chain mice
1052013032664712/05/13Human lambda light chain mice
1062013030967011/21/13Nuclease-mediated targeting with large targeting vectors
1072013031212811/21/13Promoter-regulated differentiation-dependent self-deleting cassette
1082013031212911/21/13Promoter-regulated differentiation-dependent self-deleting cassette
1092013029509711/07/13Human antibodies to fel d1 and methods of use thereof
1102013028075810/24/13Fusion polypeptides capable of activating receptors
1112013027307010/17/13Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
1122013026657410/10/13Human antibodies to human angiopoietin-like protein 4
1132013025987610/03/13Anti-hla-b*27 antibodies and uses thereof
1142013025988110/03/13Fusion polypeptides capable of activating receptors
1152013026105610/03/13Vegf antagonist formulations
1162013025172809/26/13Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
1172013025491109/26/13Adam6 mice
1182013024377509/19/13Multispecific antigen-binding molecules and uses thereof
1192013024378409/19/13Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
1202013024723409/19/13Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1212013024723509/19/13Mice that produce antigen-binding proteins with ph-dependent binding characteristics
1222013024723609/19/13Non-human animals expressing ph-sensitive immunoglobulin sequences
1232013023053109/05/13Human antibodies to clostridium difficile toxins
1242013023053309/05/13Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
1252013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1262013020949208/15/13Anti-tie2 antibodies and uses thereof
1272013021013708/15/13Methods of modifying eukaryotic cells
1282013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1292013019587808/01/13Anti-asic1 antibodies and uses thereof
1302013019887908/01/13Humanized universal light chain mice
1312013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1322013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1332013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1342013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1352013018581907/18/13Genetically modified major histocompatibility complex animals
1362013018582007/18/13Genetically modified major histocompatibility complex animals
1372013018582107/18/13Common light chain mouse
1382013017114907/04/13Anti-angptl3 antibodies and uses thereof
1392013016478606/27/13Fucosylation-deficient cells
1402013015731306/20/13High affinity antibodies to human il-6 receptor
1412013016015306/20/13Humanized light chain mice
1422013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1432013013710105/30/13Methods of modifying eukaryotic cells
1442013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1452013012983005/23/13Polymer protein microparticles
1462013013037205/23/13Enhanced expression and stability regions
1472013013038805/23/13Methods of modifying eurakyotic cells
1482013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1492013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1502013011787305/09/13Humanized il-6 and il-6 receptor
1512013010905305/02/13Genetically modified t cell receptor mice
1522013011161605/02/13Genetically modified major histocompatibility complex mice
1532013011161705/02/13Genetically modified major histocompatibility complex mice
1542013009556504/18/13Mirna-regulated differentiation-dependent self-deleting cassette
1552013009628704/18/13Restricted immunoglobulin heavy chain mice
1562013008429704/04/13Anti-erbb3 antibodies and uses thereof
1572013008463504/04/13Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1582013008526604/04/13Anti-pcsk9 antibodies with ph-dependent binding characteristics
1592013007867503/28/13High affinity human antibodies to human il-4 receptor
1602013006483403/14/13Methods for treating hypercholesterolemia using antibodies to pcsk9
1612013004549202/21/13Methods for making fully human bispecific antibodies using a common light chain
1622013003490202/07/13Fusion polypeptides capable of activating receptors
1632013002889201/31/13Method of treating osteoarthritis with an antibody to ngf
1642012032210812/20/12Adam6 mice
1652012032349712/20/12Non-hypergeometric overlap probability
1662012025809810/11/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1672012026035710/11/12Low affinity fcgr deficient mice
1682012019589608/02/12Igf-1 fusion polypeptides and therapeutic uses thereof
1692012018963507/26/12Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1702012019230007/26/12Common light chain mouse
1712012017868307/12/12Vegf antagonist formulations
1722012016468806/28/12High affinity human antibodies to human nerve growth factor
1732012013501005/31/12High affinity human antibodies to human il-4 receptor
1742012012867905/24/12Human antibodies to the glucagon receptor
1752012011464505/10/12Use of il-1 antagonists to treat pseudogout
1762012011465405/10/12Human antibodies to human tnf-like ligand 1a (tl1a)
1772012011466505/10/12Human antibodies to human rankl
1782012009756504/26/12Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1792012010014504/26/12Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
1802012010103504/26/12Vegf antagonist formulations
1812012009382404/19/12Methods for treating pruritus by administering an antibody that specifically binds human par2
1822012009657204/19/12Mice that make vl binding proteins
1832012008792904/12/12Vegf antagonist formulations for intravitreal administration
1842012008300004/05/12Neuropeptide release assay for sodium channels
1852012007679003/29/12Anti-cd48 antibodies and uses thereof
1862012007086103/22/12Human lambda light chain mice
1872012007300403/22/12Hybrid light chain mice
1882012006462103/15/12Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1892012005207203/01/12High affinity human antibodies to human il-4 receptor
1902012004544002/23/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1912012002140901/26/12Common light chain mouse
1922012001496801/19/12Stabilized formulations containing anti-ngf antibodies
1932012000369701/05/12High affinity antibodies to human il-6 receptor
1942011031834212/29/11Methods of using il-1 antagonists to treat autoinflammatory disease
1952011031153712/22/11Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
1962011030796612/15/11Mice expressing human voltage-gated sodium channels
1972011030796812/15/11Production of fertile xy animals from xy es cells
1982011029363012/01/11Antibodies to human gdf8
1992011028337611/17/11Methods of modifying eukaryotic cells
2002011026918711/03/11High affinity human antibodies to human il-18 receptor
2012011025614810/20/11Methods for treating hypercholesterolemia using antibodies to pcsk9
2022011025655610/20/11Humanized fcgr mice
2032011025658710/20/11High affinity human antibodies to human nerve growth factor
2042011025760110/20/11Vegf antagonist formulations for intravitreal administration
2052011025871010/20/11Methods of modifying eukaryotic cells
2062011019545408/11/11Common light chain mouse
2072011018917608/04/11Methods of treating diseases with dll4 antagonists
2082011018920008/04/11Methods of treating autoimmune diseases with dll4 antagonists
2092011017124107/14/11Stabilized formulations containing anti-interleukin-6 (il-6) antibodies
2102011016565007/07/11Fusion polypeptides capable of activating receptors
2112011015901506/30/11Human antibodies to human angiopoietin-like protein 4
2122011015090506/23/11Human antibodies to human delta like ligand 4
2132011015451206/23/11Humanized fc gamma r mice
2142011014593706/16/11Mice that make heavy chain antibodies
2152011010479905/05/11Multifunctional alleles
2162011008168104/07/11Human antibodies to human cd20 and using thereof
2172011006590203/17/11High affinity human antibodies to pcsk9
2182011005909503/10/11High affinity human antibodies to human protease-activated receptor-2
2192011004119602/17/11Mirna-regulated differentiation-dependent self-deleting cassette
2202011004119702/17/11Promoter-regulated differentiation-dependent self-deleting cassette
2212011002728602/03/11High affinity human antibodies to human angiopoietin-2
2222011002034201/27/11Igf-1 fusion polypeptides and therapeutic uses thereof
2232011001420801/20/11Method of treating osteoarthritis with an antibody to ngf
2242011000837401/13/11Use of il-1 antagonists to treat gout
2252010033010612/30/10Method of treating cancer with dll4 antagonist and chemotherapeutic agent
2262010033152712/30/10Readily isolated bispecific antibodies with native immunoglobulin format
2272010031662712/16/10Human antibodies to human il-6 receptor
2282010031663612/16/10Method of treating rheumatoid arthritis with an il-6r antibody
2292010030443612/02/10Fucosylation-deficient cells
2302010029110711/18/10High affinity human antibodies to human il-4 receptor
2312010029162611/18/10Enhanced expression and stability regions
2322010027993311/04/10Vegf antagonist formulations
2332010023380309/16/10Fusion polypeptides capable of activating receptors
2342010022178209/02/10Modified chimeric polypeptides with improved pharmacokinetic properties
2352010016676807/01/10High affinity human antibodies to pcsk9
2362010012981705/27/10Identifying germline competent embryonic stem cells
2372010011192105/06/10Use of il-1 antagonists to treat gout
2382010008763204/08/10Vegf-binding fusion proteins and therapeutic uses thereof
2392010007590303/25/10Lyophilized vegf antagonist formulations for intravitreal administration
2402010004725402/25/10High affinity human antibodies to human il-4 receptor
2412010004233002/18/10Non-hypergeometric overlap probability
2422010003483302/11/10High affinity human antibodies to human il-18 receptor
2432010002147601/28/10High affinity human antibodies to human il-4 receptor
2442009028584111/19/09Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
2452009027188410/29/09Es cell-derived mice from diploid host embryo injection
2462009024619910/01/09Therapeutic methods for inhibiting tumor growth with dll4 antagonists
2472009017586407/09/09Igf-1 and igf-2 chimeric polypeptides and therapeutic uses thereof
2482009016290106/25/09Inducible eukaryotic expression system
2492009015589906/18/09Modified chimeric polypeptides with improved pharmacokinetic properties



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE